Literature DB >> 16279907

Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome.

Patrick P J van der Veek1, Marlies van den Berg, Yvette E de Kroon, Hein W Verspaget, Ad A M Masclee.   

Abstract

OBJECTIVES: Imbalances in the genetically controlled pro- and anti-inflammatory cytokine production may promote ongoing low-grade inflammation after an acute gastroenteritis, and subsequently, irritable bowel syndrome (IBS) (post-infectious IBS, PI-IBS). We studied gene promoter single nucleotide polymorphisms (SNPs) of tumor necrosis factor-alpha (TNF-alpha, pro-inflammatory) and interleukin-10 (IL-10, anti-inflammatory) in IBS patients and controls.
METHODS: DNA was extracted from peripheral blood leucocytes of 111 IBS patients and 162 healthy controls. Genotype and allele frequencies were assessed by analyzing SNPs at position -308 (TNF-alpha) and -1082 and -819 (IL-10).
RESULTS: Homozygous high producers for TNF-alpha (A/A) were rare (overall prevalence 2.6%). The heterozygous TNF-alpha genotype (G/A, high producer) was significantly more prevalent in IBS compared to controls (41%vs 26%, p= 0.02). More patients (41%) than controls (30%) were positive for the A allele (p= 0.044; odds ratio (OR) 1.68, 95% confidence interval (CI) 1.01-2.79), with a similar trend for diarrhea (54%) versus constipation and alternating subtypes (<33%, p= 0.079), but not for subgroups according to a history of acute gastroenteritis. IL-10 genotypes were similarly distributed in patients and controls for both SNPs. Possession of a high producer TNF-alpha and a low producer IL-10 genotype were significantly more prevalent in IBS (9%) versus controls (3%, p= 0.035; OR 3.11, 95% CI 1.03-9.36) and in diarrhea (20%) compared to other IBS subtypes (<4%, p= 0.026).
CONCLUSIONS: Our results support the emerging hypothesis that genetically determined immune activity plays a role in the pathophysiology of IBS. Future studies in larger, clinically relevant, IBS subgroups are warranted to establish definite associations with cytokine gene polymorphisms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16279907     DOI: 10.1111/j.1572-0241.2005.00257.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  64 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

2.  Findings related to IL-8 and IL-10 gene polymorphisms in a Mexican patient population with irritable bowel syndrome infected with Blastocystis.

Authors:  Angelica Olivo-Diaz; Mirza Romero-Valdovinos; Areli Gudiño-Ramirez; Jesus Reyes-Gordillo; Diego Emiliano Jimenez-Gonzalez; Maria Elena Ramirez-Miranda; Williams Arony Martinez-Flores; Fernando Martinez-Hernandez; Ana Flisser; Pablo Maravilla
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

Review 3.  Genetic approaches to functional gastrointestinal disorders.

Authors:  Yuri A Saito; Nandita Mitra; Emeran A Mayer
Journal:  Gastroenterology       Date:  2010-02-19       Impact factor: 22.682

4.  T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome.

Authors:  Elham Barkhordari; Nima Rezaei; Mahdi Mahmoudi; Pegah Larki; Hamid Reza Ahmadi-Ashtiani; Bita Ansaripour; Maryam Alighardashi; Mohammad Bashashati; Ali Akbar Amirzargar; Naser Ebrahimi-Daryani
Journal:  Inflammation       Date:  2010-10       Impact factor: 4.092

5.  Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.

Authors:  Gareth J Sanger; Lin Chang; Chas Bountra; Lesley A Houghton
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

6.  Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 7.  Genes and environment in irritable bowel syndrome: one step forward.

Authors:  N J Talley
Journal:  Gut       Date:  2006-12       Impact factor: 23.059

Review 8.  Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation.

Authors:  Ashkan Farhadi; Jeremy-Z Fields; Ali Keshavarzian
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

Review 9.  Post-infectious irritable bowel syndrome.

Authors:  Andrew W Dupont
Journal:  Curr Gastroenterol Rep       Date:  2007-10

10.  Chronic diarrhea in travelers.

Authors:  Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.